Remember
 

$RVMD Revolution Medicines reported data demonstrating that its first-in-class KRASG12D(ON) inhibitors induced tumor regressions in a preclinical model of human pancreatic cancer carrying an oncogenic KRASG12D mutation.”


 3 days ago by corporatealerts  •  Posted on Wednesday, September 16th at 7:04 AM MST  •  0 REACTIONS

 Do You Know the Most Important and Timely Stock Plays During the Trading Week? View Our Power Rankings.
React to the Post Above with Your Unique Insight
 

Global Streams

 
PulseStream
SpecStream
UserStream
Reactions
EchoStream